Search

Author/Creator Brisson, Ryan J.

1. A pilot study of the pan‐class I PI3K inhibitor buparlisib in combination with cetuximab in patients with recurrent or metastatic head and neck cancer. Issue 11 (4th September 2019)

Authors:
Brisson, Ryan J.; Kochanny, Sara; Arshad, Saba; Dekker, Allison; DeSouza, Jonas A.; Saloura, Vassiliki; Vokes, Everett E.; Seiwert, Tanguy Y.
Journal:
Head & neck
Issue:
Volume 41:Issue 11(2019)
Page Start:
3842
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma. Issue 10 (19th February 2020)

Authors:
Kochanny, Sara E.; Worden, Francis P.; Adkins, Douglas R.; Lim, Dean W.; Bauman, Julie E.; Wagner, Stephanie A.; Brisson, Ryan J.; Karrison, Theodore G.; Stadler, Walter M.; Vokes, Everett E.; Seiwert, Tanguy Y.
Journal:
Cancer
Issue:
Volume 126:Issue 10(2020)
Page Start:
2146
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab‐resistant head and neck cancer: The MAESTRO study. Issue 14 (4th May 2020)

Authors:
Seiwert, Tanguy Y.; Kochanny, Sara; Wood, Kevin; Worden, Francis P.; Adkins, Douglas; Wade, James L.; Sleckman, Bethany G.; Anderson, Daniel; Brisson, Ryan J.; Karrison, Theodore; Stadler, Walter M.; Vokes, Everett E.
Journal:
Cancer
Issue:
Volume 126:Issue 14(2020)
Page Start:
3237
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Definitive chemoradiation for locally-advanced oral cavity cancer: A 20-year experience. (May 2018)

Authors:
Foster, Corey C.; Melotek, James M.; Brisson, Ryan J.; Seiwert, Tanguy Y.; Cohen, Ezra E.W.; Stenson, Kerstin M.; Blair, Elizabeth A.; Portugal, Louis; Gooi, Zhen; Agrawal, Nishant; Vokes, Everett E.; Haraf, Daniel J.
Journal:
Oral oncology
Issue:
Volume 80(2018)
Page Start:
16
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Immune‐related adverse events are associated with improved response, progression‐free survival, and overall survival for patients with head and neck cancer receiving immune checkpoint inhibitors. Issue 24 (21st September 2021)

Authors:
Foster, Corey C.; Couey, Marcus A.; Kochanny, Sara E.; Khattri, Arun; Acharya, Rajesh K.; Tan, Yi‐Hung Carol; Brisson, Ryan J.; Leidner, Rom S.; Seiwert, Tanguy Y.
Journal:
Cancer
Issue:
Volume 127:Issue 24(2021)
Page Start:
4565
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗